This immunomodulation may facilitate the cardiovascular protection reported in outcome studies
Weight management is a complex, long-term endeavour
Semaglutide: Weight Loss: Studies, including one published in the New England Journal of Medicine (NEJM), show an average weight loss of 15% of initial body weight with Semaglutide
Source: Jastreboff et al., NEJM 2023 TRIUMPH-4 Phase 3 (68 weeks, 445 participants) Phase 2 Type 2 Diabetes Trial (36 weeks, 281 participants) In the type 2 diabetes population, weight loss was lower than in the obesity trial which is consistent with the pattern seen across all GLP-1 drugs
Finally, we close with guidance on how to stay ahead of the curve and a call to action to harness these insights
[100] Health Peters has stated that he is on the autism spectrum, though he has not been professionally diagnosed